SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Smith A G)
 

Sökning: WFRF:(Smith A G) > (1995-1999) > Oral budesonide is ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003535naa a2200601 4500
001oai:prod.swepub.kib.ki.se:1937099
003SwePub
008240701s1997 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:19370992 URI
024a https://doi.org/10.1136/gut.41.2.2092 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Campieri, M4 aut
2451 0a Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group
264 c 1997-08-01
264 1b BMJ,c 1997
520 a Background—The use of corticosteroids in active Crohn’s disease often becomes limited by side effects. Budesonide is a potent corticosteroid with low systemic bioavailability due to an extensive first pass liver metabolism.Aims—To compare the efficacy and safety of two dosage regimens of budesonide and prednisolone in patients with active Crohn’s disease affecting the ileum and/or the ascending colon.Patients and methods—One hundred and seventy eight patients were randomised to receive budesonide controlled ileal release (CIR) capsules 9 mg once daily or 4.5 mg twice daily, or prednisolone tablets 40 mg once daily. The treatment period was 12 weeks. The primary efficacy variable was clinical remission, defined as a Crohn’s Disease Activity Index (CDAI) of 150 or less.Results—After eight weeks of treatment, remission occurred in 60% of patients receiving budesonide once daily or prednisolone and in 42% of those receiving budesonide twice daily (p=0.062). The presence of glucocorticoid associated side effects was similar in all groups; however, moon face was more common in the prednisolone group (p=0.0005). The highest frequency of impaired adrenal function, as measured by a short ACTH test, was found in the prednisolone group (p=0.0023).Conclusions—Budesonide CIR, administered at 9 mg once daily or 4.5 mg twice daily, is comparable to prednisolone in inducing remission in active Crohn’s disease. The single dose administration is as promptly effective as prednisolone and represents a simpler and safer therapeutic approach, with a considerable reduction in side effects.
700a Ferguson, A4 aut
700a Doe, W4 aut
700a Persson, T4 aut
700a Nilsson, LG4 aut
700a Malchow, H4 aut
700a Prantera, C4 aut
700a Mani, V4 aut
700a OMorain, C4 aut
700a Selby, W4 aut
700a Pallone, F4 aut
700a diPietralata, MM4 aut
700a Sjodahl, R4 aut
700a Florin, T4 aut
700a Smith, P4 aut
700a Bianchi, P4 aut
700a Lofberg, Ru Karolinska Institutet4 aut
700a Rutgeerts, P4 aut
700a Smallwood, R4 aut
700a Lamers, HW4 aut
700a TasmanJones, C4 aut
700a Hunter, JO4 aut
700a Hodgson, H4 aut
700a Danielsson, A4 aut
700a Lee, FI4 aut
700a Piacitelli, G4 aut
700a Giovanni, S4 aut
700a Ellis, A4 aut
700a Weir, DG4 aut
710a Karolinska Institutet4 org
773t Gutd : BMJg 41:2, s. 209-214q 41:2<209-214x 0017-5749x 1468-3288
856u https://gut.bmj.com/content/41/2/209.full.pdf
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1937099
8564 8u https://doi.org/10.1136/gut.41.2.209

Hitta via bibliotek

  • Gut (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy